Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06246396

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Hypertension, Resistant to Conventional Therapy Clinical Trial

Official title:
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis

Clinical Trial Summary

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: - To what extent does minocycline lower blood pressure and are these effects different across races? - Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Clinical Trial Description

One hundred twenty patients (targeting 60 White patients and 60 Black or African American [AA] patients) with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm, with similar race distribution), who are participants in the main study, will also be enrolled in a substudy that includes neuroimaging. The study will last 3 months, and will include 3 visit time points (screening, randomization visit, 3-month follow-up visit). Participants will be randomly assigned, in a 1:1 allocation, to minocycline 100 mg twice per day, or matching placebo, each provided by the study, and investigators will be blinded to treatment assignment. At the baseline and 3-month follow-up visit, subjects will undergo: - A comprehensive medical history and examination, including assessment of antihypertensive treatment history - A series of behavioral activity questionnaires - Blood tests (plasma renin activity, aldosterone, catecholamines, serum creatinine, lipid panel, hemoglobin a1c, as well as various biomarkers of immune and inflammatory activity, and gut leakiness markers) - Urine/saliva tests for antihypertensive adherence - Gut microbiota profiling via whole metagenomic sequencing of stool samples - Blood pressure (BP) measurement, including unattended office BP and 24-hour ambulatory BP Subjects enrolled in the neuroimaging substudy will also have PET/MR imaging performed at each visit. Neuroimaging activities will take place at Emory University in Atlanta, GA. At the final visit (3-month follow-up), participants will also have blood tests to measure study drug concentration, as a measure of adherence to the assigned treatment. ;

Study Design

Related Conditions & MeSH terms

  • Hypertension
  • Hypertension, Resistant to Conventional Therapy
Clinical Trial Details
NCT number NCT06246396
Study type Interventional
Source University of Florida
Contact Dana Leach, DNP
Phone 352-273-8933
Email leachdd@medicine.ufl.edu
Status Not yet recruiting
Phase Phase 4
Start date April 1, 2024
Completion date July 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02385864 - CPAP Effect on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension N/A
Completed NCT01833429 - Autonomic Dysfunction in Resistant Hypertension N/A
Completed NCT02426099 - Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension Phase 4
Recruiting NCT02623036 - The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors Phase 1
Completed NCT02587533 - Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation N/A
Recruiting NCT01863082 - Resistant Hypertension and Physical Activity Performed in a Heated Pool N/A
Terminated NCT03730519 - UK Registry for Baroreflex Activation Therapy N/A
Active, not recruiting NCT05017935 - RADIANCE Continued Access Protocol N/A
Completed NCT01520506 - Rapid Renal Sympathetic Denervation for Resistant Hypertension N/A
Active, not recruiting NCT02369081 - Optimum Treatment for Drug-Resistant Hypertension Phase 4
Withdrawn NCT04542681 - MANP in African Americans With Hypertension Phase 1
Completed NCT05395403 - Use of Automated Office Blood Pressure Monitoring N/A
Recruiting NCT02057783 - Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension N/A
Completed NCT01630928 - Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors N/A
Completed NCT01848275 - Full Length Versus Proximal Renal Arteries Ablation N/A
Completed NCT01062763 - The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension Phase 3
Completed NCT01834118 - Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension N/A
Active, not recruiting NCT01703780 - The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis N/A
Not yet recruiting NCT02042066 - Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension Phase 1
Completed NCT02667912 - Distal Renal Denervation N/A